GSK - GSK Upgrades Long-Term Outlook After Q4 Performance Shingrix Vaccine And Newly Launched RSV Vaccine Shine | Benzinga
Wednesday, GSK Plc (NYSE:GSK) reported fourth-quarter adjusted operating profit of £1.75 billion, up 10% at the actual exchange rate (AER) and up 21% at the constant exchange rate (CER).
The company’s RSV vaccine, Arexvy, hit £1.2 billion in sales in 2023 and £529 million in the fourth quarter. Approximately 6 million of the 83 million U.S. adults aged 60 and older at risk have been vaccinated with Arexvy.
The company reported sales of $10 billion (£8.1 billion), beating the consensus of $9.61 billion.
Also Read: GSK Cuts More Stake In Its Spun-Off Consumer-Healthcare Business Haleon, Raises Over £900M.
Shingrix, a vaccine against herpes zoster (shingles), grew 17% in the full year to £3.5 billion and 23% in the quarter to £908 ...